NVO (Novo Nordisk AS) Accounts Payable : $4,050 Mil (As of Dec. 2024)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS Accounts Payable?

Novo Nordisk AS's Accounts Payable for the quarter that ended in Dec. 2024 was $4,050 Mil.

Novo Nordisk AS's quarterly Accounts Payable declined from Jun. 2024 ($4,292 Mil) to Sep. 2024 ($3,584 Mil) but then increased from Sep. 2024 ($3,584 Mil) to Dec. 2024 ($4,050 Mil).

Novo Nordisk AS's annual Accounts Payable increased from Dec. 2022 ($2,219 Mil) to Dec. 2023 ($3,746 Mil) and increased from Dec. 2023 ($3,746 Mil) to Dec. 2024 ($4,050 Mil).

Novo Nordisk AS Accounts Payable Historical Data

The historical data trend for Novo Nordisk AS's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Accounts Payable Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

934.85

1,347.82

2,219.45

3,746.42

4,050.21

Novo Nordisk AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable	Get a 7-Day Free Trial															3,746.42	1,895.97	4,292.00	3,584.25	4,050.21

Novo Nordisk AS Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Novo Nordisk AS Accounts Payable Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.